According to a new report, published by KBV research, The Global Herpes Simplex Virus Treatment Market size is expected to reach $2.1 billion by 2028, rising at a market growth of 3.0% CAGR during the forecast period.
The Acyclovir segment is showcasing a CAGR of 3.6% during (2022 - 2028). One of the most popular antiviral medications for herpes, acyclovir is mainly used to treat oral herpes as well as herpes simplex encephalitis and is sold under the brand names Zovirax and Sitavig. It is a purine nucleoside analog that penetrates viral DNA and changes it into acyclovir triphosphate to stop virus replication. Omeprazole exerted significantly stronger impacts on acyclovir activity as well as raised acyclovir activity at lower doses, which increased acyclovir-mediated implications on HSV-1 and 2 replication in a dose-dependent manner.
The Herpes simplex virus-1 Infection segment is leading the Global Herpes Simplex Virus Treatment Market by Type in 2021 thereby, achieving a market value of $1.6 billion by 2028. The segment growth is fueled by the rising risk of HSV-1 transmission. The infection can be spread by oral-genital contact, contact with infected saliva, contact with infected sores, or even by direct touch with the infected sores. Additionally, the segment's development is anticipated to be aided by the rising prevalence of HSV-1 encephalitis (HSE), a severe and rare neurological condition brought on by the virus.
The Hospital Pharmacies segment has shown the growth rate of 3.2% during (2022 - 2028). Hospital pharmacies serve as the main centers for the diagnosis as well as treatment of patients with herpes infections in both developing and developed countries. Rising disease prevalence and a steady influx of patients into hospitals are anticipated to support the segment's development. This market is also being driven by appropriate reimbursement policies and an increase in the number of hospitals that have pharmacies.
The North America market dominated the Global Herpes Simplex Virus Treatment Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $725.4 Million by 2028. The Asia Pacific market is exhibiting a CAGR of 3.9% during (2022 - 2028). Additionally, The Europe market would showcase a CAGR of 2.8% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/herpes-simplex-virus-treatment-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Abbott Laboratories, Pfizer, Inc., Amneal Pharmaceuticals, Inc., GlaxoSmithKline PLC, Teva Pharmaceuticals Industries Ltd., Glenmark Pharmaceuticals Limited, Fresenius SE & Co. KGaA, Novartis AG, Viatris, Inc., and Emcure Pharmaceuticals Limited.
By Drug Type
By Type
By Distribution Channel
By Geography
Companies Profiled
Unique Offerings 
